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Abstract
BACKGROUND
Perianal fistulae are either primary (idiopathic) or secondary [commonly
associated with Crohn’s disease, (CD)]. It is assumed, although not proven, that
the pathophysiology differs.
AIM
To systematically compare the clinical phenotypes, cytokine and phosphoprotein
profiles of idiopathic and CD-related perianal fistulae.
METHODS
Sixty-one patients undergoing surgery for perianal fistula were prospectively
recruited (48 idiopathic, 13 CD) into a cohort study. Clinical data, including the
Perineal Disease Activity Index (PDAI) and EQ-5D-5L were collected. Biopsies of
the fistula tract, granulation tissue, internal opening mucosa and rectal mucosa
were obtained at surgery. Concentrations of 30 cytokines and 39 phosphoproteins
were measured in each biopsy using a magnetic bead multiplexing instrument
and a chemiluminescent antibody array respectively. Over 12000 clinical and
23500 laboratory measurements were made.
RESULTS
The PDAI was significantly higher (indicating more active disease) in the CD
group with a mean difference of 2.40 (95%CI: 0.52-4.28, P = 0.01). Complex
pathoanatomy was more prevalent in the CD group, namely more multiple
fistulae, supralevator extensions, collections and rectal thickening. The IL-12p70
concentration at the internal opening specimen site was significantly higher
(median difference 19.7 pg/mL, 99%CI: 0.2-40.4, P = 0.008) and the IL-1RA/IL-1β
ratio was significantly lower in the CD group at the internal opening specimen
site (median difference 15.0, 99%CI = 0.4-50.5, P = 0.008). However in the
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remaining 27 cytokines and all 39 of the phosphoproteins across the four biopsy
sites, no significant differences were found between the groups.
CONCLUSION
CD-related perianal fistulae are more clinically severe and anatomically complex
than idiopathic perianal fistulae. However, overall there are no major differences
in cytokine and phosphoprotein profiles.
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©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: We systematically compared idiopathic and Crohn’s perianal fistulae, but did
not find major differences in their cytokine and phosphoprotein profiles. Although more
research is needed, our results support the thesis that biological agents effective in
Crohn’s disease-related perianal fistulae may also have a role in selected surgically-
intractable idiopathic perianal fistulae.
Citation: Haddow JB, Musbahi O, MacDonald TT, Knowles CH. Comparison of cytokine and
phosphoprotein profiles in idiopathic and Crohn’s disease-related perianal fistula. World J
Gastrointest Pathophysiol 2019; 10(4): 42-53
URL: https://www.wjgnet.com/2150-5330/full/v10/i4/42.htm
DOI: https://dx.doi.org/10.4291/wjgp.v10.i4.42
INTRODUCTION
Perianal  fistulae  occur  in  1.04  to  2.32  per  10000  people  per  annum[1,2],  are  more
common in males (ratio about 2:1), and cause significant physical and psychosocial
morbidity. Fistulotomy can achieve successful healing at one year in 75% of patients[3],
but is not always possible when the fistula involves a significant portion of the anal
sphincter complex. Sphincter-sparing operations such as a fistula plug, advancement
flap and ligation of the internal fistula tract only have success rates at one year of 55%,
53% and 42% respectively[3].  In Crohn’s disease (CD), perianal fistulae can heal in
response to biological agents in 68% of patients[4]. Treatments for perianal fistulae
could be improved if we had a better understanding of their pathophysiology.
The aetiology and pathophysiology of perianal fistulae is still unclear. The majority
(90%)  are  considered  to  be  primary  or  idiopathic[5].  In  such  patients,  Parks’
cryptoglandular theory prevails, supposing infection of an anal gland as the primary
lesion. Suppuration then penetrates through the internal anal sphincter creating a
fistula tract[6].
In contrast, secondary fistulae, which can be associated with inflammatory bowel
disease, tuberculosis and human immunodeficiency virus[5,7]. are assumed to arise
from inflammation of the anorectal mucosa. By far the most common association is
with CD, where perianal involvement is found in around one third of patients[8].
Scharl and Rogler summarised the immunological evidence for the pathogenesis of
fistulae  in  CD[9].  In  their  proposed  mechanism,  an  epithelial  defect  caused  by
inflammation or  injury allows pathogen-associated molecular  patterns  from the
microbiota to gain entry to the lamina propria and induce various pathways mediated
by TNF-α, transforming growth factor beta (TGF-β), IL-13, matrix metalloproteinases
(MMPs) and integrin-αvβ6. These drive epithelial-to-mesenchymal transition, which
allows cell invasion and migration, resulting in a penetrating fistula tract lined by
transitional cells.
Research to date into the pathophysiology of idiopathic and CD-related perianal
fistula  has  evolved  separately  due  to  the  underlying  assumption  that  they  are
fundamentally different. Some previous studies made the comparison between these
two  types  by  use  of  specific  histological,  microbiological  and  immunological
methods[10-13]. Overall their conclusions supported this underlying assumption, but
testing this  assumption was  not  their  objective.  We therefore  hypothesised that
idiopathic  and  CD-related  perianal  fistulae  are  different  and  aimed to  test  this
systematically by comparing their clinical phenotypes, cytokine and phosphoprotein
profiles.
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MATERIALS AND METHODS
Patients
We conducted a prospective cohort study between March 2014 and April 2015 within
a NHS University Hospital (approved by Queen’s Square Research Ethics Committee,
reference number 14/LO/0071). Adults with an idiopathic or CD-related perianal
fistula  requiring  surgical  intervention  were  included.  Rectal,  intestinal  and
subcutaneous fistulae were excluded.
One hundred and thirty consecutive patients were identified from outpatient and
inpatient referrals, multidisciplinary meetings and surgical waiting lists. Twenty-two
were not approached (simply for logistic reasons), 28 were ineligible and 11 declined.
Thus we recruited 61 patients, 48 (79%) idiopathic and 13 (11%) CD-related (Supple-
mentary Figure 1).
Patient characteristics were in keeping with the general epidemiology (Supple-
mentary Table 1). None had a stoma. In the CD group, six had previous abdominal
fistulae, six had previous abdominal surgery, and seven were naïve to anti-TNF-α
antibody therapy. All had a combination of radiological, endoscopic and histological
features of CD. Idiopathic patients had CD excluded by radiological and endoscopic
imaging  in  32  (67%)  and clinical  assessment  alone  in  16  (33%).  Reasons  for  not
imaging patients were patient declined (4) and not clinically indicated (16).
Healthy controls
For the purposes of studying the rectal biopsies, we approached nine consecutive
patients undergoing diagnostic colonoscopy for non-inflammatory conditions. Two
declined and one was excluded due to ileal inflammation found during colonoscopy.
Thus we recruited six healthy controls for rectal biopsies (Supplementary Table 2).
Five were female and the mean age was 53.5 years (SD = 20.6).
Data and specimen collection
We collected clinical information, Perineal Disease Activity Index (PDAI)[14], EuroQol
EQ-5D-5L[15],  and intra-operative findings,  which were assisted by pre-operative
magnetic resonance imaging in 49 (80%) patients. PDAI and EQ-5D-5L at baseline
were measured in all but one participant.
Biopsy specimens were taken from: (1) The fistula tract wall; (2) Tract granulation
tissue (if present); (3) Internal opening mucosa (if present); and (4) Rectal mucosa.
Specimens were kept on ice and processed within four hours. One patient did not
undergo biopsy due to unavailability of research staff.
Processing of tissue specimens
Fresh  specimens  were  prepared  under  a  microscope.  Those  reserved  for
phosphoprotein quantification were snap frozen and stored at -80 °C. Those reserved
for cytokine quantification were immediately incubated in 300 µL serum free HL-1
medium (Lonza, Cambridge, United Kingdom) containing 10 U/mL penicillin and
streptokinase,  32  μg/mL  gentamicin  and  1  in  100  Lglutamine  (Sigma-Aldrich,
Gillingham,  United  Kingdom)  at  37  °C  and  5%  carbon  dioxide  for  24  h.  The
supernatant was stored at -80 °C.
Cytokine quantification
We used 30-plex Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel
(EMD Millipore, Billerica, MA, United States) to quantify the concentrations of 30
cytokines and chemokines: EGF, Eotaxin, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-10, IL-
12P40, IL-12P70, IL-13, IL-15, IL-17, IL-1RA, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-
7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, TNF-β, RANTES, and VEGF (Supple-
mentary  Table  3).  Measurements  were  made  using  a  MAGPIX  multiplexing
instrument  (Luminex  Corporation,  Austin,  TX,  United  States).  We followed the
manufacturer’s  recommended  quality  control  procedures  to  ensure  validity[16].
Specimen supernatants were analysed in singlet due to resource constraints, however,
quality  controls  were  measured  in  duplicate  and  95% of  these  were  within  the
accepted margin of error.
Phosphoprotein quantification
The method of phosphoprotein quantification was based on previous work within our
laboratory[17]. Cells were lysed using 100 μL of radioimmunoprecipitation assay buffer
containing one microlitre of Phosphatase Inhibitor Cocktail 2 and one microlitre of
protease  inhibitor  in  dimethyl  sulfoxide  (Sigma-Aldrich,  Gillingham,  United
Kingdom) and a manual ultrasonic cell disruptor intermittently for 10 min at 4 °C. We
then  separated  off  the  supernatant  and  performed  a  Bradford  Assay  (Bio-Rad
Laboratories Inc., Hercules, CA, United States) to estimate the protein concentration.
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PathScan RTK Signaling Antibody Array, Chemiluminescent Readout (Cell Signaling
Technology,  Danvers,  Massachusetts)  was used to quantify the phosphorylation
status of 28 RTKs and 11 signalling nodes: EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3,
FGFR1,  FGFR3,  FGFR4,  InsR,  IGF-IR,  TrkA/NTRK1,  TrkB/NTRK2,  Met/HGFR,
Ron/MST1R, Ret, ALK, PDGFR, c-Kit/SCFR, FLT3/Flk2, M-CSFR/CSF-1R, EphA1,
EphA2, EphA3, EphB1, EphB3, EphB4, Tyro3/Dtk, Axl, Tie2/TEK, VEGFR2/KDR,
Akt/PKB/Rac (at Thr308), Akt/PKB/Rac (at Ser473), p44/42 MAPK, S6 Ribosomal
Protein, c-Abl, IRS-1, Zap-70, Src, Lck, Stat1 and Stat3 (Supplementary Table 4). A
total of 113 µg of protein from each whole cell lysate was probed on the array. The
chemiluminescent  signals  were  detected  on  Amersham  Hyperfilm  ECL  (GE
Healthcare  Life  Sciences,  Buckinghamshire,  United Kingdom),  digitised using a
lightbox and camera (Nikon D70 digital camera with a Nikon 18-70 mm 1:3.5-4.5G DX
lens, Nikon Corporation, Tokyo, Japan) and measured using ImageQuant TL 2005
(GE Healthcare Life Sciences, Pittsburg, PA, United States). The measurements were
normalised to give pixel intensities ranging from zero to 100%. Prior experiments
determined a positivity threshold of 20%.
Statistical analysis
Sample size was based on feasibility (recruitment period).  Further,  there is  little
consensus on sample size estimations for assays used in this  study and no prior
relevant data upon which to base a calculation.
Data  were  entered  into  a  validated  database  using  Access  2010  (Microsoft,
Redmond  WA,  United  States).  Double-entering  of  a  random  10%  data  sample
estimated the error rate at 0.6%. Proprietary software (SPSS Statistics version 22, IBM,
Armonk, NY, United States) was used to analyse data, and Excel 2010 (Microsoft,
Redmond, WA, United States) to produce the heat map charts. Parametric and non-
parametric methods were used for normal and non-normal data respectively. We
considered P < 0.05 to be statistically significant. When comparing the cytokine and
phosphoprotein data where multiple  comparisons were made,  using P  <  0.01 as
statistically significant was considered an appropriate correction. This study was
reviewed by a biomedical statistician. The STROBE guidelines were followed for
reporting[18].
RESULTS
Clinical data
The PDAI was significantly higher (indicating more active disease) in the CD group
with a mean difference of 2.40 (95%CI: 0.52-4.28, P = 0.01). The EQ visual analogue
scores (VAS) and index values were similar between the groups. Multiple fistulae
were more prevalent in CD patients (23% vs 4%). The distribution of the different
types of fistulae under the Parks’ classification was the same between the groups,
with trans-sphincteric being by far the commonest. Prevalence of a high primary tract
and horseshoe extensions  were  similar  between groups.  However,  supralevator
extensions and collections were commoner in the CD group (31% vs 6% and 92% vs
33% respectively).  Rectal  thickening,  reflecting proctitis,  was almost  exclusively
observed in the CD group (Table 1).
Cytokine profiles
All four specimen sites yielded substantial levels of IL-1RA, IL-6, MCP-1, RANTES,
VEGF,  G-CSF  and  IL-8.  GM-CSF,  IFN-α2,  IP-10,  MIP-1α  and  MIP-1β  were  also
moderately abundant in the granulation tissue, internal opening and rectal mucosa.
Granulation  tissue,  compared  to  the  other  specimen  sites,  yielded  higher
concentrations of G-CSF, IL-10, IL-1RA, and IL-1β (Figure 1).
Only two cytokines demonstrated significant differences between the idiopathic
and CD groups. IL-12p70 concentration at the internal opening was higher in patients
with CD (28.3 pg/mL, IQR = 7.4-50.1 vs idiopathic 7.4 pg/mL, 4.6-12.7). The median
difference was 19.7 pg/mL (99%CI: 0.2-40.4, P = 0.008). The IL-1RA/IL-1β ratio was
significantly  lower  in  CD  group  at  the  internal  opening  (3.3,  IQR  =  1.8-7.6  vs
idiopathic 19.0, 4.3-51.2). The median difference was 15.0 (99%CI: 0.4-50.5, P = 0.008)
(Figure 2).
There were no significant differences between the groups for any other cytokine
concentrations at the four specimen sites. There were also no significant differences in
the cytokine concentrations in the rectal  mucosa between the CD group and the
healthy controls (Supplementary Figure 2).
Phosphoprotein profiles
All four specimen sites yielded signals across both patient groups for EGFR, HER2,
WJGP https://www.wjgnet.com November 13, 2019 Volume 10 Issue 4
Haddow JB et al. Perianal fistula immunopathology
45
Table 1  Clinical features
Idiopathic Crohn’s Disease P value
Mean PDAI (SD) 5.67 (2.76) 8.07 (3.99) 0.01a
Mean EQ VAS (SD) 71.2 (21.1) 63.4 (20.2) 0.22
Mean EQ index (SD) 0.734 (0.259) 0.715 (0.214) 0.80
Seton in situ, n (%) 21 (44) 3 (23) 0.22
Number of fistulae, n (%) 0.09
  Single unbranched 31 (65) 3 (23)
  Single branched 15 (31) 7 (54)
  Multiple 2 (4) 3 (23)
Parks’ classification, n (%) 0.54
  Inter-sphincteric 7 (15) 1 (8)
  Trans-sphincteric 38 (79) 10 (77)
  Supra-sphincteric 3 (6) 2 (15)
High primary tract 15 (31) 6 (46) 0.34
Secondary tract(s), n (%) 0.02a
  None 31 (65) 4 (31)
  Infralevator 14 (29) 5 (38)
  Supralevator 3 (6) 4 (31)
Horseshoe, n (%) extension(s) 12 (25) 5 (38) 0.49
Collection(s) , n (%) 16 (33) 12 (92) < 0.001a
Thickened rectum, n (%) 1 (2) 7 (54) < 0.001a
Perineal Disease Activity Index, EuroQoL visual analogue score and index measured at pre-operative clinic
assessment. Continuous data was compared using t-test. Discrete data compared using Fisher’s Exact test. P
< 0.05 was considered significant.
aP < 0.05. PDAI: Perineal Disease Activity Index; SD: Standard deviation; EQ: EuroQol; VAS: Visual analogue
score.
HER3, FGFR1, FGFR3, FGFR4, Stat1, and Stat3. In the rectal mucosa, we observed
positive signals for InsR, IGF-1R, c-Kit, Tie2, Akt at phosphorylation site Thr308, S6
Ribosomal Protein, IRS-1 and Src in both patient groups and the healthy controls.
There were no significant differences in phosphoprotein levels between the patient
groups at any of specimen sites (Figure 3).
When comparing the CD group with the healthy controls at the rectal  mucosa
specimen site,  the levels  of  six  phosphoproteins were significantly higher in the
healthy  controls :  EphA1,  EphA2,  EphB1,  EphB4,  Tyro3  and  VEGFR2
(Supplementary Figure 3). Example microarray images are shown in Figure 4. There
were no differences the remaining 33 phosphoproteins.
DISCUSSION
To  our  knowledge,  this  is  the  largest  study  to  date  to  systematically  compare
idiopathic and CD-related perianal fistulae in a well-defined patient cohort. Both
groups  displayed a  broad distribution  of  disease  characteristics  from simple  to
complex.
CD-related perianal fistulae were clinically more severe
In the CD group, the PDAI was significantly higher and complex pathoanatomy was
more  prevalent,  supporting  the  commonly-held  belief  that  CD-related  perianal
fistulae are more severe and complex than idiopathic. However, this did not translate
to  differences  in  EQ-5D,  probably  because  this  generic  health  measure  lacked
sensitivity to demonstrate a relatively small clinical difference.
Cytokine and phosphoprotein profiles of idiopathic and CD-related perianal fistulae
were similar
Detailed  profiling  of  30  different  cytokines  and  chemokines  and  39  different
phosphoproteins at four different biopsy sites showed that the idiopathic and CD
groups  were  broadly  similar.  Our  cytokine  profiling  is  comparable  to  and
substantially more extensive than previous studies[13,19,20]  and our phosphoprotein
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Figure 1
Figure 1  Median cytokine concentrations (log-10 scale) in the supernatants from 24-h fresh tissue cultures
using a 30-plex Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, Billerica,
MA, United States) and a MAGPIX multiplexing instrument (Luminex Corporation, Austin, TX, United States).
The median IL-12p70 concentration at the internal opening was higher in the Crohn’s disease group (a). The median
difference was 19.7 pg/mL (Hodges-Lehman, 99%CI: 0.2-40.4; Mann-Whitney U, P = 0.008). The IL-1RA/IL-1β
concentration ratio was significantly lower in the Crohn’s disease group at the internal opening (b). The median
difference was 15.0 (99%CI: 0.4-50.5, P = 0.008). There were no other statistically significant differences between the
groups in the remaining 27 cytokines at the four biopsy sites. 1Results should be interpreted cautiously as they were
below the minimum detectable concentration for the assay. Id: Idiopathic; CD: Crohn’s disease; HC: Healthy controls;
F: Fistula tract; G: granulation tissue; I: Internal opening; R: Rectal mucosa.
profiling is the first to be reported in perianal fistula disease.
Only four previous studies directly compared idiopathic and CD-related perianal
fistulae.  Bataille  et  al[10,11]  found  both  types  had  a  lining  of  granulation  tissue
containing histiocytes and capillaries, a lumen filled with nuclear debris, neutrophils
and lymphocytes, and markers indicative of epithelial-to-mesenchymal transition.
However, CD-related perianal fistulae featured more CD45R0 positive T cells and
CD20  positive  B  cells,  whilst  idiopathic  fistulae  featured  more  CD68  positive
macrophages. Kirkegaard et al[12] found both types had similar MMP-3 and MMP-9
upregulation. Tozer found both types had similar levels of IL-2, IL-4, IL-6, IP-10, TNF-
α and IFN-γ in tissue culture supernatants, but also reported higher numbers of T
cells, lower expression of dendritic cell homing markers and fewer CD65 positive
macrophages in CD-related perianal fistulae[13].
It is well established that there are significant differences in the cytokine expression
in  CD-affected  intestinal  mucosa,  compared  with  healthy  mucosa,  namely  pro-
inflammatory cytokines IL-1,  TNF-α,  IL-6,  IL-8,  IL-12,  IL-17 and IL-21,  and anti-
inflammatory cytokines IL-10 and TGF-β[21]. Thus, notwithstanding Tozer’s results
mentioned above, similar differences might be seen in idiopathic compared with CD-
related perianal  fistulae.  To broaden this line of  enquiry,  we analysed the tissue
culture supernatants for 30 different cytokines. Only two measurements showed a
significant difference between the groups: IL-12p70 and the IL-1RA/IL-1β ratio, both
at the internal opening.
IL-12 is a proinflammatory cytokine produced by dendritic cells and macrophages.
It comprises two subunits, IL-12p35 and IL-12p40, which combine into IL-12p70. The
IL-12  receptor  is  found mainly  on  T  cells  and natural  killer  cells.  IL-12  induces
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Figure 2
Figure 2  Boxplots for IL-12p70 concentration (left) and IL-1RA/IL-1β concentration ratios (right) in the supernatants from 24-h fresh tissue cultures using a
30-plex Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, Billerica, MA, United States) and a MAGPIX multiplexing
instrument (Luminex Corporation, Austin, TX, United States). At the internal opening, differences between the idiopathic and Crohn’s disease groups were
statistically significant. Median difference in IL-12p70 concentration at the internal opening was 19.7 pg/mL (Hodges-Lehman, 99%CI: 0.2-40.4; Mann-Whitney U, P =
0.008). The median difference in IL-1RA/IL-1β at the internal opening was 15.0 (Hodges-Lehman, 99%CI: 0.4-50.5; Mann-Whitney U, P = 0.008). Circle marker, outlier
within 1.5 × interquartile range (IQR); Star marker, outlier out with 1.5 × IQR. One outlier not shown to limit Y-axis scale.
production of IFN-γ, promotes T helper 1 cell differentiation and forms a link between
innate  resistance  and  acquired  immunity[22].  It  plays  an  important  role  in  CD
pathogenesis. The expression of IL-12 is upregulated in CD mucosa[23].  This study
found significantly higher concentrations of IL-12p70 at the internal opening in the
CD group, suggesting a similarly important role for IL-12 in CD-related perianal
fistula  and  may  represent  a  difference  in  its  pathophysiology  compared  with
idiopathic perianal fistula disease. However, these data need to be interpreted with
caution, as the 99% confidence interval came close to zero.
IL-1α and IL-1β mediate immune and inflammatory responses. They are primarily
produced by tissue macrophages, monocytes,  fibroblasts,  and dendritic cells and
enable transmigration of immune cells to the site of inflammation. IL-1β concentration
is increased in inflamed CD colonic mucosa[24]. We found low concentrations in the
fistula  tract,  internal  opening and rectal  mucosa,  with no significant  differences
between the groups. This might suggest that the role of IL-1 in perianal fistula differs
from inflamed CD colonic mucosa. However, we found the IL-1RA/IL-1ß ratio at the
internal opening was significantly lower in the CD group, which is in keeping with
previous reports in inflamed CD colonic mucosa[24].
RTKs and intracellular signalling pathways control and regulate cell behaviour[25].
Many intracellular signalling pathways are upregulated in CD[17]. For example, signal
transducer and activator of transcription 4 in T helper 1 cells is activated by IL-12,
driving IFN-γ and TNF-α production[26]. Indeed an anti-IL-12 monoclonal antibody,
ustekinumab, is of clinical benefit in CD[27]. We analysed 39 different phosphoproteins
involved  in  epithelial  cell  signalling,  wound  healing,  inflammation  and  T  cell
activation,  and  found  no  significant  differences  in  the  phosphoprotein  profiles
between idiopathic and CD-related perianal fistulae. We were also interested to see if
fistula  immunopathology changes over  time.  However,  due to  only ten patients
having fistulae less than 12 mo old, this subgroup analysis was not possible.
Cell signalling in rectal mucosa may be suppressed in both idiopathic and CD-
related perianal fistula disease
Comparison of  the rectal  mucosa in  the idiopathic  and CD groups with healthy
controls found no differences in the cytokine profiles. However, in the rectal mucosa,
the signals in both disease groups appeared to be suppressed compared with the
healthy controls. This difference was significant for six phosphoproteins (EphA1,
EphA2, EphB1, EphB4, Tyro3 and VEGFR2) when comparing the healthy controls
with the CD group.
The first four are RTKs from the Ephrin subfamily. Ephrin signalling is important
in controlling cellular proliferation in the crypts and differentiation of enterocytes on
the villi. Loss of ephrin receptor and ephrin signalling appears to contribute to wound
healing  defects  as  in  inflammatory  bowel  disease[28].  Our  study  suggests  that
suppression of ephrin receptor expression in the rectal mucosa may be a pathological
feature  in  patients  with  both  idiopathic  and  CD-related  perianal  fistulae.  The
consequence of this conclusion is potentially important for two reasons: (1) Idiopathic
and CD-related perianal  fistulae may be similar  in their  immunopathology with
regards to ephrin signaling; and (2) Abnormalities in those with idiopathic perianal
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Figure 3
Figure 3  Median signal intensities (%) quantifying the phosphorylation status of receptor tyrosine kinases in
the cell lysates of the fresh tissue samples using the PathScan RTK Signaling Antibody Array,
Chemiluminescent Readout (Cell Signaling Technology, Danvers, Massachusetts). The signal intensities were
similar in the idiopathic and Crohn’s disease groups at the four specimen sites. When the Crohn’s disease group was
compared to healthy controls, a statistically significant difference (Mann Witney U, P < 0.01) was seen for EphA1,
EphB1, EphB4, Tyro3 and VEGFR2. Id: Idiopathic; CD: Crohn’s disease; HC: Healthy controls; F: Fistula tract; G:
Granulation tissue; I: Internal opening; R: Rectal mucosa.
fistulae  might  not  be  confined  to  the  peri-fistula  tissue,  a  notion  that  has  not
previously been reported.
Tyro3 is a RTK that, along with Axl and Mertk, and their ligands Gas6 and Protein
S,  makes  up  the  Tyro3-Axl-Mertk  (TAM)  signalling  pathway.  This  pathway  is
involved in the negative regulation of inflammation, removal of apoptotic cells and
potential induction of the tissue repair response. In inflammatory bowel disease, TAM
signalling  is  suppressed,  which,  in  the  presence  of  mucosal  injury,  leads  to  an
accumulation of apoptotic neutrophils and a failure of macrophages to acquire an
alternative activation state[29]. Our study with respect to the rectal mucosa in the CD
group is consistent with this. However, it also suggests that suppression of Tyro3 may
also occur in the rectal mucosa of those with idiopathic perianal fistulae, further
supporting the notion described above.
VEGFR2  is  the  principle  RTK  that  transmits  VEGF  signals  in  the  vascular
endothelium. The principle effect of VEGFR2 activation is angiogenesis, which is a
feature of  both health and disease.  VEGFR2 may be suppressed in quiescent CD
colonic mucosa, compared with healthy controls[30]. In the rectal mucosa, we found
that  VEGFR2 levels  were lower in patients  both with idiopathic  and CD-related
perianal fistulae, compared with healthy controls. This suggests that expression of this
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Figure 4
Figure 4  Example microarray images acquired to quantify the phosphorylation status of receptor tyrosine
kinases in the cell lysates of the fresh tissue samples using the PathScan RTK Signaling Antibody Array,
Chemiluminescent Readout (Cell Signaling Technology, Danvers, Massachusetts). Fistula tract samples from
(A) idiopathic and (B) Crohn’s disease patients. Granulation tissue samples from (C) idiopathic and (D) Crohn’s
disease patients. Internal opening samples from (E) idiopathic and (F) Crohn’s disease patients. Control array
containing lysis buffer only (G), showing an absent signal from all test spots and the negative control spots (-), and
100% signal from the positive control spots (+). Healthy control rectal mucosa (H) showing positive signal from
numerous spots including EphA1 (19), EphB1 (22), EphB4 (24), Tyro3/Dtk (25) and VEGFR (28). Idiopathic rectal
mucosa (I) showing significantly lower signal from the same highlighted spots. Crohnâs disease rectal mucosa (J),
again showing significantly lower signal from the same highlighted spots.
RTK may be suppressed in these diseases.
Limitations
Only 13 patients were recruited to the CD group. Previous comparative studies have
reported with similar sample sizes[10-13].  Preferential medical management in CD-
related  perianal  fistulae  could  also  have  introduced selection  bias,  and  referral
patterns  could  have  skewed  the  types  of  fistulae  included  to  the  more  severe
(especially in relation to the idiopathic group where many were tertiary referrals).
Techniques and assays were taken from similar experiments on intestinal mucosa
published by our group[17]. The assays have not previously been used on fistula tract
and granulation tissue, however their performance was likely to be similar as the
cellular compositions of these tissues are similar.
The majority of the CD group were receiving immunomodulatory therapy, and half
had received anti-TNF-α. This may have attenuated differences between the groups.
However, the effect of anti-TNF-α therapy at the molecular level is unknown. One
study  found  that  mucosal  TNF-α  concentrations  are  unaltered  by  anti-TNF-α
therapy[19]. Including only treatment-naïve patients would have mitigated this, but
recruitment would have been difficult into given that most are primarily managed
medically.
Conclusion
CD-related  perianal  fistulae  may  often  be  clinically  more  severe  and  complex.
However,  they do not  substantially differ  in their  expression of  a  large panel  of
cytokines and phosphoproteins (Table 2).
Implications for future research
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Table 2  Summary of comparisons between idiopathic and Crohn's disease perianal fistulae
Similarities Differences
PDAI Significantly higher PDAI in Crohn’s disease
EQ-5D-5L Similar EQ VAS and EQ index
Morphology Similar distribution of types by Parks’
classification
More multiple fistulae in Crohn’s disease
Similar prevalence of high fistulae and horseshoe
extensions
Significantly more supralevator extensions,
collections and rectal thickening in Crohn’s
disease
Cytokine concentrations Similar concentrations of 27 cytokines at all four
biopsy sites
Significantly higher IL-12p70 concentration at
internal opening in Crohn’s disease
(EGF, eotaxin, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-
10, IL-12p40, IL-13, IL-15, IL-17, IL-1α, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1α,
MIP-1β, TNF-α, TNF-β, RANTES and VEGF)
Significantly lower IL-1RA/IL-1β ratio
concentration at internal opening in Crohn’s
disease
Phosphoprotein concentrations Similar levels of 39 phosphoproteins at the four
specimen sites
(EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3,
FGFR1, FGFR3, FGFR4, InsR, IGF-IR,
TrkA/NTRK1, TrkB/NTRK2, Met/HGFR,
Ron/MST1R, Ret, ALK, PDGFR, c-Kit/SCFR,
FLT3/Flk2, M-CSFR/CSF-1R, EphA1, EphA2,
EphA3, EphB1, EphB3, EphB4, Tyro3/Dtk, Axl,
Tie2/TEK, VEGFR2/KDR, Akt/PKB/Rac (at
Thr308), Akt/PKB/Rac (at Ser473), p44/42 MAPK,
S6 Ribosomal Protein, c-Abl, IRS-1, Zap-70, Src,
Lck, Stat1 and Stat3)
See supplementary material for cytokine and phosphoprotein names in full. PDAI: Perineal Disease Activity Index; EQ: EuroQol; VAS: Visual analogue
score.
Despite the acknowledged limitations (particularly regarding sample size in the CD
group  and  the  fact  that  some  CD  patients  were  receiving  immunomodulatory
therapy), our data contributes to an emerging theory that idiopathic and CD-related
perianal fistulae may not be as immunologically distinct as previously supposed. This
line of reasoning opens the possibility that biological agents effective in CD-related
perianal fistulae may also have a role in selected idiopathic perianal fistulae especially
when recent randomised trial data have exposed the general limitations of surgery[3].
We acknowledge however that research is warranted.
ARTICLE HIGHLIGHTS
Research background
Perianal fistulae are common and cause significant physical and psychosocial morbidity. Current
treatments come with a significant failure rate. Idiopathic perianal fistulae are thought to arise
from a primary infection of an anal gland, which leads to penetrating suppuration and fistula
formation.  Crohn’s  disease  (CD)-related  perianal  fistulae  is  thought  to  arise  from altered
inflammatory pathways within the mucosa.
Research motivation
The aetiology and pathophysiology of perianal fistulae is still unclear. A better understanding
could lead to better treatments. Most research to date has assumed idiopathic and CD-related
fistulae to be fundamentally different. However this assumption has never been tested.
Research objectives
We hypothesised that idiopathic and CD-related perianal fistulae are different and aimed to test
this  systematically  by  comparing  their  clinical  phenotypes,  cytokine  and phosphoprotein
profiles.
Research methods
We conducted a prospective cohort study within a university hospital. Sixty-one consecutive
patients undergoing surgery for perianal fistula were recruited. Clinical data, pre- and post-
operative Perineal Disease Activity Index (PDAI) and EQ-5D-5L scores were measured. Biopsies
of the fistula tract, granulation tissue, internal opening mucosa and rectal mucosa were obtained
at  surgery.  These  were  processed  in  our  laboratory  to  measure  30  cytokines  and  39
phosphoproteins. To our knowledge, this is the largest study to date to systematically compare
idiopathic and CD-related perianal fistulae in a well-defined patient cohort.
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Research results
The PDAI was significantly higher and complex pathoanatomy was more prevalent in the CD
group, supporting the commonly-held belief that CD-related perianal fistulae are more severe
and complex than idiopathic. IL-12p70 concentration at the internal opening was higher and the
IL-1RA/IL-1β ratio was significantly lower at the internal opening in patients with CD. There
were no significant differences between the groups for any other cytokine concentrations at the
four specimen sites. There were also no significant differences in phosphoprotein levels between
the patient groups at any specimen site.
Research conclusions
CD-related perianal fistulae are often clinically more severe and complex. However, they do not
substantially differ in their expression of a large panel of cytokines and phosphoproteins.
Research perspectives
Our data contributes to an emerging theory that idiopathic and CD-related perianal fistulae may
not be as immunologically distinct as previously supposed. This line of reasoning opens the
possibility that biological agents effective in CD-related perianal fistulae may also have a role in
selected idiopathic perianal fistulae especially when recent randomised trial data have exposed
the general limitations of surgery. Further research is warranted.
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